) --




) hit a new 52-week high Tuesday as it is currently trading at $43.48, above its previous 52-week high of $43.47 with 497,821 shares traded as of 12:05 p.m. ET. Average volume has been 503,500 shares over the past 30 days.

Cepheid has a market cap of $2.1 billion and is part of the


sector and


industry. Shares are up 25.4% year to date as of the close of trading on Monday.

Cepheid, a molecular diagnostics company, engages in developing, manufacturing, and marketing integrated systems for testing in the clinical market, as well as for application in legacy biothreat, industrial, and partner markets. The company has a P/E ratio of 98, below the average electronics industry P/E ratio of 364.2 and above the S&P 500 P/E ratio of 17.7.

  • Sign up for TheStreet's FREE Dividend and Income Investor Newsletter

TheStreet Ratings rates Cepheid as a


. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and weak operating cash flow. You can view the full

Cepheid Ratings Report


See all

52-week high stocks

or get investment ideas from our

investment research center